Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

被引：0

作者：

Yongliang Feng

Jing Chen

Tian Yao

Yue Chang

Xiaoqing Li

Rongqin Xing

Hong Li

Ruixue Xie

Xiaohong Zhang

Zhiyun Wei

Shengcai Mu

Ling Liu

Lizhong Feng

Suping Wang

机构：

[1] Shanxi Medical University,Department of Epidemiology, School of Public Health

[2] Shanxi Medical University,Center of Clinical Epidemiology and Evidence Based Medicine

[3] Shanxi Provincial Center for Disease Control and Prevention,undefined

[4] Shanxi Provincial Key Laboratory for Major Infectious Disease Response,undefined

[5] Outpatient Department of Shanxi Aviation Industry Group Co. LTD,undefined

来源：

Infectious Diseases of Poverty | / 10卷

关键词：

COVID-19; Inactivated SARS-CoV-2 vaccine; Immunogenicity; Safety; High-risk occupational population; Randomized controlled trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
Feng, Yongliang
Chen, Jing
Yao, Tian
Chang, Yue
Li, Xiaoqing
Xing, Rongqin
Li, Hong
Xie, Ruixue
Zhang, Xiaohong
Wei, Zhiyun
Mu, Shengcai
Liu, Ling
Feng, Lizhong
Wang, Suping
INFECTIOUS DISEASES OF POVERTY, 2021, 10 (01)
[2] Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
Feng Yongliang
Chen Jing
Yao Tian
Chang Yue
Li Xiaoqing
Xing Rongqin
Li Hong
Xie Ruixue
Zhang Xiaohong
Wei Zhiyun
Mu Shengcai
Liu Ling
Feng Lizhong
Wang Suping
贫困所致传染病（英文）, 2021, 10 (06) : 27 - 37
[3] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
Kandeil, Ahmed
Mostafa, Ahmed
Hegazy, Rehab R.
El-Shesheny, Rabeh
El Taweel, Ahmed
Gomaa, Mokhtar R.
Shehata, Mahmoud
Elbaset, Marawan A.
Kayed, Ahmed E.
Mahmoud, Sara H.
Moatasim, Yassmin
Kutkat, Omnia
Yassen, Noha N.
Shabana, Marwa E.
GabAllah, Mohamed
Kamel, Mina Nabil
Abo Shama, Noura M.
El Sayes, Mohamed
Ahmed, Amira N.
Elalfy, Zahraa S.
Mohamed, Bassim M. S. A.
Abd El-Fattah, Safa N.
El Hariri, Hazem Mohamed
Abdel Kader, Mona
Azmy, Osama
Kayali, Ghazi
Ali, Mohamed A.
VACCINES, 2021, 9 (03) : 1 - 15
[4] Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Xia, Shengli
Duan, Kai
Zhang, Yuntao
Zhao, Dongyang
Zhang, Huajun
Xie, Zhiqiang
Li, Xinguo
Peng, Cheng
Zhang, Yanbo
Zhang, Wei
Yang, Yunkai
Chen, Wei
Gao, Xiaoxiao
You, Wangyang
Wang, Xuewei
Wang, Zejun
Shi, Zhengli
Wang, Yanxia
Yang, Xuqin
Zhang, Lianghao
Huang, Lili
Wang, Qian
Lu, Jia
Yang, Yongli
Guo, Jing
Zhou, Wei
Wan, Xin
Wu, Cong
Wang, Wenhui
Huang, Shihe
Du, Jianhui
Meng, Ziyan
Pan, An
Yuan, Zhiming
Shen, Shuo
Guo, Wanshen
Yang, Xiaoming
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (10): : 951 - 960
[5] CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
Jin, Lairun
Li, Zhuopei
Zhang, Xiaoyin
Li, Jingxin
Zhu, Fengcai
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
[6] Safety and Immunogenicity Outcomes of an Inactivated Viral Vaccine against SARS-CoV-2 (Covaxin®)
Sinha, Parul
Gupta, Megha
Vijayvergia, Varunika
Jain, Sushil Kumar
Jain, Dinesh Kumar
Gupta, Sandeep
Rathore, Monika
Vyas, Nitya
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022, 16 (09) : DC12 - DC17
[7] Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
Fatemeh Gholami
Ramin Hamidi Farahani
Ahmad Karimi Rahjerdi
Mohammadreza Ahi
Ali Sheidaei
Kimiya Gohari
Zahra Rahimi
Akram Ansarifar
Pouria Basiri
Milad Moradi
Arash Jahangiri
Kosar Naderi
Soheil Ghasemi
Pezhman Khatami
Mohsen Honari
Samane Khodaverdloo
Mohammad Shooshtari
Hajar Mehr Azin
Sohrab Moradi
Batool Shafaghi
Hossein Allahyari
Arina Monazah
Ali Khodaei Poor
Zahra Taghva
Hooman Bakhshande
Mohammad Karimi Nia
Masoud Solaymani Dodaran
Mohsen Forooghizade
BMC Infectious Diseases, 23
[8] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Chu, Laurence
McPhee, Roderick
Huang, Wenmei
Bennett, Hamilton
Pajon, Rolando
Nestorova, Biliana
Leav, Brett
VACCINE, 2021, 39 (20) : 2791 - 2799
[9] Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years
Gholami, Fatemeh
Farahani, Ramin Hamidi
Rahjerdi, Ahmad Karimi
Ahi, Mohammadreza
Sheidaei, Ali
Gohari, Kimiya
Rahimi, Zahra
Ansarifar, Akram
Basiri, Pouria
Moradi, Milad
Jahangiri, Arash
Naderi, Kosar
Ghasemi, Soheil
Khatami, Pezhman
Honari, Mohsen
Khodaverdloo, Samane
Shooshtari, Mohammad
Azin, Hajar Mehr
Moradi, Sohrab
Shafaghi, Batool
Allahyari, Hossein
Monazah, Arina
Poor, Ali Khodaei
Taghva, Zahra
Bakhshande, Hooman
Nia, Mohammad Karimi
Dodaran, Masoud Solaymani
Forooghizade, Mohsen
BMC INFECTIOUS DISEASES, 2023, 23 (01)
[10] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
Fernandes, Eder Gatti
Silva Lopez-Lopes, Giselle Ibette
Silva, Valeria Oliveira
Yamashiro, Rosemeire
Rolim Madureira, Karen Cristina
Gallo, Juliana Failde
Lindoso, Jose Angelo
Sato, Helena Keico
D'Avila Limeira de Araujo, Nubia Virginia
Bacciotte Ramos Nerger, Maria Ligia
Macedo Brigido, Luis Fernando
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2021, 63

← 1 2 3 4 5 →